UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053184
Receipt number R000060427
Scientific Title A multicenter prospective cohort study for investigating the visuality of palisade vessels at the gastroesophageal junction (GOJ) after acid secretion inhibitor in patients with reflux esophagitis
Date of disclosure of the study information 2023/12/21
Last modified on 2024/04/22 21:48:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A multicenter prospective cohort study for investigating the visuality of palisade vessels at the gastroesophageal junction (GOJ) after acid secretion inhibitor in patients with reflux esophagitis

Acronym

GOJ-P

Scientific Title

A multicenter prospective cohort study for investigating the visuality of palisade vessels at the gastroesophageal junction (GOJ) after acid secretion inhibitor in patients with reflux esophagitis

Scientific Title:Acronym

GOJ-P

Region

Japan


Condition

Condition

Reflux esophagitis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the changes of visuality of palisade vessels at the gastro-oesophageal juntion before and after administration of vonoprazan 20 mg/day for more than four week in patients with reflux esophagitis

Basic objectives2

Others

Basic objectives -Others

observation

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Improvement rate of endoscopic score after administration of vonoprazan 20mg/day for more than four weeks
(rate of patients in whom endoscopic score increased more than one after administration of vonoprazan compared with that before administration)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients aged more than 20 years
2) Patients who were diagnosed as reflux esophagitis in the pilot studies
3) Patients who do not take vonoprazan 20mg/day
4) Patients who will take vonoprazan 20mg/day for more than four weeks and will undergo oesophagogastroduodenoscopy after administration of vonoprazan for more than four weeks
5) Patients who enrolled the pilot studies within one month
6) Patients in whom a written consent can be obtained

Key exclusion criteria

1) Patients who do not want to undergo oesophagogastroduodenoscopy
2) Patients who are judged as inappropriate for participating in this study by the researchers

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Toshio
Middle name
Last name Uraoka

Organization

Gunma University Hospital

Division name

Department of Gastroenterology and Hepatology

Zip code

371-8511

Address

3-39-15 Showa-machi, Maebashi, Gunma 371-8511 Japan

TEL

027-220-8148

Email

uraoka@gunma-u.ac.jp


Public contact

Name of contact person

1st name Shiko
Middle name
Last name Kuribayashi

Organization

Gunma University Hospital

Division name

Department of Gastroenterology and Hepatology

Zip code

371-8511

Address

3-39-15 Showa-machi, Maebashi, Gunma 371-8511 Japan

TEL

0272-220-8137

Homepage URL


Email

shikokuri@gunma-u.ac.jp


Sponsor or person

Institute

Gunma University Hospital

Institute

Department

Personal name



Funding Source

Organization

JDDW GOJZ consortium

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Gunma University Hospital Clinical Research Review Board

Address

3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan

Tel

027-220-8740

Email

ciru_hitotaisho-irb@ml.gunma-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 12 Month 05 Day

Date of IRB

2023 Year 12 Month 08 Day

Anticipated trial start date

2024 Year 01 Month 09 Day

Last follow-up date

2026 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is an exploratory study. The sample size was estimated as 80 based on number of patients in pilot studies and prevalence of reflux esophagitis.


Management information

Registered date

2023 Year 12 Month 21 Day

Last modified on

2024 Year 04 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060427


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name